Organization
Ludwig-Maximilians-Universität München
1 abstract
Abstract
Breaking primary checkpoint inhibitor resistance: Interim analysis of a multicenter phase II study by intermittent application of an alkylating agent among patients with metastatic melanoma.Org: Department of Dermatology, Ludwig-Maximilians-Universität München, University Hospital Regensburg, University Hospital Würzburg, Universitätsklinikum Erlangen,